Research programme: hyperbranched polyglycerol-based therapeutics - Sitka Biopharma

Drug Profile

Research programme: hyperbranched polyglycerol-based therapeutics - Sitka Biopharma

Alternative Names: HPG-docetaxel; STK 01

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sitka Biopharma
  • Class Glycerols
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer

Most Recent Events

  • 26 Jun 2017 Sitka Biopharma, Cancer Research UK and Cancer Research technology agree to co-develop STK 01 for Bladder Cancer
  • 26 Jun 2017 Sitka Biopharma plans a phase I trial for Bladder cancer in UK (Intravesicular instillation)
  • 03 Dec 2013 Preclinical trials in Bladder cancer in Canada (Intravesicular instillation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top